🔬Deep Research

MRNA — Moderna · catalysts, narrative & risks

·22 sourcesMRNA forecast →

Context

Moderna (NASDAQ: MRNA) is a Cambridge, Massachusetts biotechnology company built around messenger RNA (mRNA) vaccines and therapeutics, led by CEO Stéphane Bancel [20]. As of early November 2026, the stock trades in the low-to-mid $220s–$250s range (point-in-time figures vary across sources: ~$228–$251 depending on the snapshot) and carries a market capitalization roughly in the $88–$100B range, depending on the day's price [7], [16], [17], [19], [20]. It is up many-fold year to date, a run that is now the central story for both bulls and bears [2], [9], [10].


AI-assisted research from the K3vl4r desk — not personalized investment advice. More research →